AI-generated summary
The authors report a small single-blind randomized trial of intravaginal blue LED light (415 nm) added to standard therapy for recurrent vulvovaginal candidiasis in 13 women. At 180 days, 76.9% of participants showed a 50% or greater reduction in signs and symptom scores, and 53.8% had negative Candida cultures, with the therapy described as well tolerated.
- Participants
- 13
- Who or what was studied
- Women with recurrent vulvovaginal candidiasis (mean age 28.92 years)
- Wavelengths
- 415 nm
- Limits stated in the abstract
- The trial was small, with only four to five participants per group and a short overall follow-up, and the authors state that larger studies with longer follow-up are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode, Control group, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.